New Developments in Peptide Receptor Radionuclide Therapy.
Details
Serval ID
serval:BIB_0D0FD6FEB45A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
New Developments in Peptide Receptor Radionuclide Therapy.
Journal
Journal of nuclear medicine
ISSN
1535-5667 (Electronic)
ISSN-L
0161-5505
Publication state
In Press
Peer-reviewed
Oui
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Publication Status: aheadofprint
Abstract
Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a molecular target. The development of imaging companions gave rise to the concept of radiotheranostics, important for in vivo tumor detection, characterization, staging but also, and more importantly, for individual patient selection and treatment. The success of somatostatin receptor targeting paved the way for the clinical translation of other peptide-based radiopharmaceuticals targeting, e.g. the receptors Cholecystokinin 2, Gastrin Releasing Peptide (GRPR), Neurokinin-1 and C-X-C motif chemokine 4 (CXCR4). While historically the Auger emitter <sup>111</sup> In and the high-energy β- emitter <sup>90</sup> Y were used, the vast majority of PRRT are currently performed with the medium-energy β- emitter <sup>177</sup> Lu, while α emitters are increasingly studied in various clinical applications.
Keywords
G-protein coupled receptors, Neuroendocrine, Peptides, Radionuclide Therapy, alpha radiation therapy, beta radiation therapy, targeted radionuclide therapy, theranostics
Pubmed
Web of science
Publisher's website
Open Access
Yes
Create date
28/03/2022 16:13
Last modification date
08/05/2023 9:48